BARCELONA—In patients with previously irradiated locally recurrent prostate cancer, salvage high-dose-rate brachytherapy (HDRB) was an effective and safe treatment option. The 3rd ESTRO Forum (April 24-28, 2015) heard data from a retrospective analysis with 60 patients that found HDRB had acceptable late genitourinary toxicity after external beam radiotherapy. Study author Manuel Galdeano Rubio MD from Institut Català d’Oncologia discussed the findings with Oncology Times reporter Sarah Maxwell.
You may also like...
Immunotherapy: Standard of Care in Waiting for Non Small-Cell Lung Cancer 20 Apr, 2015
Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed 28 Mar, 2015
Preventing ER-Positive Breast Cancer—Latest from IBIS 1, 2 and 3 20 Mar, 2015
Combined Intracavitary/Interstitial Brachytherapy: New benchmark for Cervical Cancer 5 May, 2015
- Previous story Phase-III Randomized ARCON Trial: Comment from Hans Kaanders
- Next story Accelerated Partial Breast Irradiation for Women over 70 with Early Breast Cancer Improved Outcomes
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014
- First enterovirus 71 vaccines effective against hand, foot and mouth diseaseFebruary 28, 2014